BlackfinBio Ltd (BFB), a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases, has announced that it has acquired the Parkinson’s patent portfolio from OXB.
BFB intends to initially develop this technology as part of its BFB-201 programme focused on dopamine deficiency diseases.
Peter Nolan CEO of BFB said: “We are delighted to take assignment of this patent portfolio which we look forward to developing as part of our BFB-201 programme.
Professor Mimoun Azzouz, academic founder of BFB said: “We are excited to attract this assignment to the BFB pipeline, offering a fantastic opportunity to apply a single product across a wide range of dopamine deficiency diseases.”
BlackfinBio is a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases. The pipeline comprises BFB-101, an IND stage AP4B1 replacement AAV gene therapy for spastic paraplegia 47 – an ultra-rare genetic neurological disease for which no treatment currently exists. BFB-201 is a preclinical stage gene therapy approach using three gene fusion (AADC-TH-CH) to treat several dopamine deficiency disorders.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!